Pharmaceuticals News and Research

RSS

University of Copenhagen researchers develop new cell line to investigate brain drugs

Researchers from the Department of Pharmacy at the University of Copenhagen have developed a cell line, which may be used to investigate new drugs and help predict whether they are able to enter the brain.

18 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.

13 Jan 2016

UM SOM to team up with industry to develop vaccine for preventing deadly bacterial infections

The Center for Vaccine Development at the University of Maryland School of Medicine will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients.

13 Jan 2016

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

Study opens new avenues for treatment of prostate cancer in obese patients

Obesity has direct consequences on health and is associated with the onset of aggressive cancers, but the mechanisms underlying this phenomenon are little known. Researchers from the Institut de Pharmacologie et he Biologie Structurale (CNRS/Université Toulouse III - Paul Sabatier) have recently elucidated one of these mechanisms in prostate cancer, one of the most common cancers in men: in obese patients, the adipose tissue surrounding the prostate gland facilitates the propagation of tumor cells outside the prostate.

13 Jan 2016

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Laboratorios SALVAT, S.A. and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited, jointly announced today the signing of an exclusive License and Supply Agreement for the marketing and distribution of Duoxal ear drops (patented combination solution of Ciprofloxacin and Fluocinolone Acetonide) in the People's Republic of China, Hong Kong S.A.R., Macau S.A.R., and Taiwan and an option to add Thailand to the contractual territory.

12 Jan 2016

Food preservative delivers one-two punch to cancer, antibiotic-resistant bacteria

Nisin, a naturally occurring food preservative that grows on dairy products, delivers a one-two punch to two of medicine's most lethal maladies: cancer and deadly, antibiotic-resistant bacteria.

12 Jan 2016

Novel drug shows promise against metastatic breast cancer in mouse models

A doctor treating a patient with a potentially fatal metastatic breast tumor would be very pleased to find, after administering a round of treatment, that the primary tumor had undergone a change in character - from aggressive to static, and no longer shedding cells that can colonize distant organs of the body.

12 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Vagus nerve stimulation effective in inhibiting cortical spreading depression

According to a study led by scientists at Massachusetts General Hospital, Harvard Medical School published in the journal Pain, vagus nerve stimulation (VNS) was found to suppress cortical spreading depression (CSD).

12 Jan 2016

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.

12 Jan 2016

AiCure closes $12.25 million in Series A fundraising round

AiCure, an artificial intelligence company connecting the world's patients to better treatments and improved health, has closed a Series A fundraising round with $12.25 million. The consortium is led by New Leaf Venture Partners, with additional participation from Pritzker Group Venture Capital, Tribeca Venture Partners, and Biomatics Capital, established by Boris Nikolic, former Chief Advisor for Science and Technology to Bill Gates.

11 Jan 2016

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.

11 Jan 2016

Blocking brain inflammation could protect against memory, behaviour changes

A University of Southampton-led study has found that blocking a receptor in the brain responsible for regulating immune cells could protect against the memory and behaviour changes seen in the progression of Alzheimer's disease.

11 Jan 2016

UTA researchers map out chemical mechanism of key enzyme found in autism, Alzheimer's and Down syndrome

Biochemists at The University of Texas at Arlington are mapping the catalytic processes of sulfur-oxidizing enzymes to improve understanding of the chemical imbalances found in patients with autism, Alzheimer's disease and Down syndrome.

11 Jan 2016

UCSD Skaggs School of Pharmacy, Janssen R&D partner to identify new therapeutic targets for Chagas disease

Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego have entered into a research collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to identify new therapeutic targets for Chagas disease, a parasitic infection that is the leading cause of heart failure in Latin America.

8 Jan 2016

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

JJHWS, Plug and Play Tech Center partner to support companies developing wellness solutions

Johnson & Johnson Health and Wellness Solutions, Inc. today announced a collaboration with Plug and Play Tech Center, a global investor and technology accelerator, to support innovative, early-stage companies developing direct-to-consumer solutions that enhance wellness.

7 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

Pharmaceuticals News and Research

University of Copenhagen researchers develop new cell line to investigate brain drugs

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

UM SOM to team up with industry to develop vaccine for preventing deadly bacterial infections

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

Study opens new avenues for treatment of prostate cancer in obese patients

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Food preservative delivers one-two punch to cancer, antibiotic-resistant bacteria

Novel drug shows promise against metastatic breast cancer in mouse models

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Vagus nerve stimulation effective in inhibiting cortical spreading depression

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

AiCure closes $12.25 million in Series A fundraising round

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Blocking brain inflammation could protect against memory, behaviour changes

UTA researchers map out chemical mechanism of key enzyme found in autism, Alzheimer's and Down syndrome

UCSD Skaggs School of Pharmacy, Janssen R&D partner to identify new therapeutic targets for Chagas disease

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

JJHWS, Plug and Play Tech Center partner to support companies developing wellness solutions

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Event guide: World ADC San Diego eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring